News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mirabilis Medica Closes $10.5 Million Series A Extension to Commercialize Non-Invasive Treatment of Uterine Fibroids



8/21/2007 6:10:49 AM

SEATTLE--(BUSINESS WIRE)--Mirabilis Medica, a privately held medical device company, today announced the closing of a $10.5 million extension to its series A financing, which was originally led by Charter Life Sciences and vSpring Capital last year. The series A extension was led by Arboretum Ventures of Ann Arbor MI, and included Split Rock Partners, Dow Venture Capital, and an individual investor. The funding will be used to continue developing and testing its image-guided High Intensity Focused Ultrasound (HIFU) system for treatment of gynecological diseases.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES